<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490827</url>
  </required_header>
  <id_info>
    <org_study_id>PM-01</org_study_id>
    <nct_id>NCT01490827</nct_id>
  </id_info>
  <brief_title>Argus® II Retinal Prosthesis System Post-Market Surveillance Study</brief_title>
  <official_title>Argus® II Retinal Prosthesis System Post-Market Surveillance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Sight Medical Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Sight Medical Products</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post-market surveillance study is conducted in the European Economic Area where Argus II
      has been CE certified for use in outer retinal degeneration patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to monitor the use of Argus II in a larger population than
      available within pre-market approval studies. Safety data will be monitored to ensure
      continued acceptability of risks to study participants, and an attempt will be made to
      include all eligible and willing participants implanted with Argus II. Measures of visual
      function that may contribute to device improvements will also be gathered and evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor discontinued the Argus II product
  </why_stopped>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>up to 3 years from time of implantation</time_frame>
    <description>nature and rate of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual function</measure>
    <time_frame>up to 3 years from time of implantation</time_frame>
    <description>Square localization, direction of motion, grating visual acuity</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">52</enrollment>
  <condition>Outer Retinal Degeneration</condition>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Argus II Retinal Prosthesis</arm_group_label>
    <description>Patients implanted with an Argus II Retinal Prosthesis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be selected from eligible patients who have been implanted with the Argus II
        retinal prosthesis at the enrolling center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adults, age 25 year or older

          -  with severe to profound outer retinal degeneration (not including Age-related Macular
             Degeneration)

          -  Have some residual light perception. If no residual light perception remains, the
             retina must be able to respond to electrical stimulation;

          -  Have previous history of useful form vision

          -  Have consented to participate in the study

          -  Had an Argus II Retinal Prosthesis surgically implanted 14 days (± 7 days) prior to
             enrollment (at Baseline Visit) in the study

          -  At the time of the Baseline Visit, do not suffer from non-ophthalmic serious adverse
             events (e.g. coma, myocardial infarction, etc.).

        Exclusion Criteria:

          -  Ocular diseases or conditions that could prevent Argus II from working (e.g. optic
             nerve disease, central retinal artery or vein occlusion, history of retinal
             detachment, trauma, severe strabismus, etc.)

          -  Ocular structures or conditions that could prevent the successful implantation of the
             Argus II Implant or adequate healing from surgery (e.g. extremely thin conjunctiva;
             axial length &lt;20.5 mm or &gt; 26 mm; corneal ulcers; choroidal neovascularization in the
             area of the intended tack location, etc.)

          -  Ocular diseases or conditions (other than cataracts) that prevent adequate
             visualization of the inner structures of the eye (e.g. corneal opacity)

          -  Pre-disposition to eye rubbing

          -  Any disease or condition that prevents understanding or communication of informed
             consent, study demands, and testing protocols, including:

               -  cognitive decline including diagnosed forms of dementia and/or progressive
                  neurologic disease,

               -  psychiatric disease including diagnosed forms of depression;

               -  does not speak a principal language associated with the region, and

               -  deafness or selective frequency hearing loss that prevents hearing device alarms
                  and alerts

          -  Participants who are pregnant or wish to become pregnant during the course of the
             study

          -  Participation in another investigational drug or device study that may conflict with
             the objectives, follow-up or testing of this study;

          -  Conditions likely to limit life to less than 1 year from the time of inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Marie Ripley</last_name>
    <role>Study Director</role>
    <affiliation>Second Sight Medical Products</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Augenklinik des Staedtischen Klinikums</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Wurttemberg</state>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar - Technical University</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Ophthalmology - University of Koln</name>
      <address>
        <city>Koln</city>
        <state>NRW</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftsklinikum Saar, Department of Ophthalmology</name>
      <address>
        <city>Sulzbach</city>
        <state>Saarland</state>
        <zip>66280</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Schleswig-Holstein, Department of Ophthalmology</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RWTH University Eye Clinic</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf, Klinik u. Poliklinik fur Augenheilkunde</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR, Klinik und Poliklinik für Augenheilkunde</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pisa Eye Surgery Department</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS 15 Alta Padovana Hospital</name>
      <address>
        <city>Camposampiero</city>
        <state>Veneto</state>
        <zip>35012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>da Cruz L, Coley BF, Dorn J, Merlini F, Filley E, Christopher P, Chen FK, Wuyyuru V, Sahel J, Stanga P, Humayun M, Greenberg RJ, Dagnelie G; Argus II Study Group. The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss. Br J Ophthalmol. 2013 May;97(5):632-6. doi: 10.1136/bjophthalmol-2012-301525. Epub 2013 Feb 20.</citation>
    <PMID>23426738</PMID>
  </reference>
  <reference>
    <citation>Weiland JD, Faraji B, Greenberg RJ, Humayun MS, Shellock FG. Assessment of MRI issues for the Argus II retinal prosthesis. Magn Reson Imaging. 2012 Apr;30(3):382-9. doi: 10.1016/j.mri.2011.12.005. Epub 2012 Jan 20.</citation>
    <PMID>22260934</PMID>
  </reference>
  <results_reference>
    <citation>Schaffrath K, Schellhase H, Walter P, Augustin A, Chizzolini M, Kirchhof B, Grisanti S, Wiedemann P, Szurman P, Richard G, Greenberg RJ, Dorn JD, Parmeggiani F, Rizzo S. One-Year Safety and Performance Assessment of the Argus II Retinal Prosthesis: A Postapproval Study. JAMA Ophthalmol. 2019 May 30. doi: 10.1001/jamaophthalmol.2019.1476. [Epub ahead of print]</citation>
    <PMID>31145440</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

